HK Stock Market Move | CIRRUS (02507) rises more than 5% in the morning, the company has ample orders on hand. Institutions believe that the feedback on the new model is worth looking forward to.
Sinopec Engineering (02507) rose more than 5% in the morning trading, as of the time of writing, it was up 4.31% at HK$38.28, with a turnover of HK$578.89 million.
CIRRUS (02507) rose more than 5% in the morning, rising by 4.31% as of the time of publication to HK$38.28, with a turnover of HK$57.8989 million.
On the news front, CIRRUS Aircraft recently announced its annual performance, achieving a total revenue of $1.35 billion, a year-on-year increase of 13.1%; net profit of $139 million, both reaching historical highs. Due to the surge in demand after the G7+ announcement, the company maintained a record order backlog during the year of record deliveries. The order quantity and booking quantity increased by 728 aircraft, an increase of 95 compared to the previous year.
Cathay Haitong released a research report stating that the company's revenue and profit have steadily increased over the past 25 years, with a full order backlog, and expecting market feedback for new aircraft models in 26 years. The bank believes that the continuous introduction of new aircraft models with higher pricing and added value will benefit the company's future demand. In addition, it is expected that with the continuous increase in the company's aircraft holdings and the enrichment of service business types, the company's service-related business will have greater growth potential in the future.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


